{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:55:37Z","timestamp":1790574937084,"version":"4.1.0"},"reference-count":82,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["ebm-journal.org"],"crossmark-restriction":true},"short-container-title":["Exp. Biol. Med."],"abstract":"<jats:p>Mitochondrial metabolism is increasingly recognized as an active determinant of tumor growth and cancer-cell adaptation rather than solely a source of cellular energy. Mitochondrial metabolism supports tumor anabolism, while mitochondrial DNA (mtDNA) alterations can affect respiratory chain function, redox homeostasis, and adaptation to changing tumor environments. At the same time, tumor metabolism is heterogeneous and flexible and cannot be explained by a uniform Warburg model. Tumor cells may use glycolysis, oxidative phosphorylation (OXPHOS), or hybrid glycolysis\/OXPHOS states, with the relative contribution of these pathways varying across tumor types, tumor regions, microenvironmental conditions, and therapeutic pressure. This metabolic flexibility may contribute to tumor progression, metastasis, and treatment resistance. In this review, we examine mitochondrial metabolic phenotypes in cancer and their relevance to therapeutic targeting and surgical oncology. We discuss OXPHOS-dependent tumor states, mitochondrial DNA mutations, mitochondrial dynamics, reactive oxygen species, mitochondrial membrane potential, and mitochondrial regulation of intrinsic apoptosis. We further evaluate therapeutic strategies targeting these vulnerabilities, including OXPHOS inhibitors, BCL-2 family inhibitors, ROS modulators, mitochondrial dynamics modulators, mitochondrial genome-editing approaches, and emerging mitochondria-directed immunotherapies. Clinical evidence indicates that broad mitochondrial-targeted interventions may be limited by toxicity, narrow therapeutic windows, limited efficacy, or lack of benefit in unselected populations, supporting the need for metabolic phenotype classification, biomarker-guided patient selection, and rational combination strategies. Particular emphasis is placed on the potential integration of mitochondrial targeting with surgical oncology. Metabolic heterogeneity within tumors and the tumor microenvironment may influence treatment response, residual disease, and recurrence. Emerging approaches such as mass spectrometry imaging, single-cell sequencing, and spatial transcriptomic analysis may allow metabolic features to be mapped within anatomically defined regions of surgical specimens and linked to specific malignant, stromal, and immune-cell populations. Such approaches may help identify OXPHOS-dependent, glycolytic, and metabolically flexible tumor populations and provide clinically relevant biomarkers for treatment selection and monitoring. Overall, mitochondrial vulnerabilities represent a context-dependent therapeutic opportunity rather than a universal metabolic target. Better characterization of mtDNA alterations, metabolic plasticity, spatial heterogeneity, and tumor-specific metabolic dependencies will be important for developing biomarker-guided mitochondrial therapies and for determining how these interventions can be safely integrated into neoadjuvant, adjuvant, and perioperative cancer care.<\/jats:p>","DOI":"10.3389\/ebm.2026.11244","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:10:10Z","timestamp":1790572210000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Mitochondrial metabolic plasticity in cancer: hybrid bioenergetic states and translational targeting in surgical oncology"],"prefix":"10.3389","volume":"251","author":[{"given":"Debdeep","family":"Chattopadhyay","sequence":"first","affiliation":[{"name":"Post-Graduate & Research Department of Biotechnology, St. Xavier\u2019s College (Autonomous)","place":["Kolkata, West Bengal, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya Lakshmi","family":"Rajendran","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, School of Medicine, Kyungpook National University","place":["Daegu, Republic of Korea"]},{"name":"Cardiovascular Research Institute, Kyungpook National University","place":["Daegu, Republic of Korea"]},{"name":"BK21 FOUR KNU Convergence Educational Program of Biomedical Sciences for Creative Future Talents, School of Medicine, Kyungpook National University","place":["Daegu, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nida","family":"Mubin","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Case Western Reserve University School of Medicine","place":["Cleveland, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Durva","family":"Tendulkar","sequence":"additional","affiliation":[{"name":"Department of Applied Microbiology, Vellore Institute of Technology","place":["Vellore, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thoudam Debraj","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Laboratory, All India Institute of Medical Sciences (AIIMS)","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhrojyoti","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Independant Researcher","place":["Kolkata, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh Kumar","family":"Jha","sequence":"additional","affiliation":[{"name":"Department of Zoology, Kalindi College, University of Delhi","place":["New Delhi, India"]},{"name":"Department of Biotechnology Engineering and Food Technology, Chandigarh University","place":["Mohali, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Gangadaran","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, School of Medicine, Kyungpook National University","place":["Daegu, Republic of Korea"]},{"name":"Cardiovascular Research Institute, Kyungpook National University","place":["Daegu, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong-Cheol","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, School of Medicine, Kyungpook National University","place":["Daegu, Republic of Korea"]},{"name":"Cardiovascular Research Institute, Kyungpook National University","place":["Daegu, Republic of Korea"]},{"name":"Department of Nuclear Medicine, Kyungpook National University Hospital","place":["Daegu, Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cmet.2020.06.019","article-title":"Mitochondrial metabolism as a target for cancer therapy","volume":"32","author":"Vasan","year":"2020","journal-title":"Cell Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5980","DOI":"10.1158\/1538-7445.AM2024-5980","article-title":"Abstract 5980: cancer therapeutic and prevention strategy targeting mutated mitochondria DNA","volume":"84","author":"Nagase","year":"2024","journal-title":"Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"115531","DOI":"10.1016\/j.bcp.2023.115531","article-title":"OXPHOS inhibitors, metabolism and targeted therapies in cancer","volume":"211","author":"Cadassou","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41591-022-02103-8","article-title":"Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials","volume":"29","author":"Yap","year":"2023","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/CCO.0b013e32834deb9e","article-title":"The warburg effect in 2012","volume":"24","author":"Bayley","year":"2012","journal-title":"Curr Opin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1089\/ars.2016.6750","article-title":"Heterogeneity in cancer metabolism: new concepts in an old field","volume":"26","author":"Gentric","year":"2017","journal-title":"Antioxid Redox Signal"},{"key":"B7","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.cmet.2019.08.013","article-title":"Mechanisms and implications of metabolic heterogeneity in cancer","volume":"30","author":"Kim","year":"2019","journal-title":"Cell Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"700629","DOI":"10.3389\/fonc.2021.700629","article-title":"Mechanisms governing metabolic heterogeneity in breast cancer and other tumors","volume":"11","author":"Patra","year":"2021","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/neuonc\/nou121","article-title":"Intratumoral heterogeneity and intraclonal plasticity: from warburg to oxygen and back again","volume":"16","author":"Conrad","year":"2014","journal-title":"Neuro-Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3390\/cancers13040762","article-title":"Linking metabolic reprogramming, plasticity and tumor progression","volume":"13","author":"Shuvalov","year":"2021","journal-title":"Cancers"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1158\/0008-5472.CAN-16-2074","article-title":"Modeling the genetic regulation of cancer metabolism: interplay between glycolysis and oxidative phosphorylation","volume":"77","author":"Yu","year":"2017","journal-title":"Cancer Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e0309700","DOI":"10.1371\/journal.pone.0309700","article-title":"Dual inhibition of oxidative phosphorylation and glycolysis exerts a synergistic antitumor effect on colorectal and gastric cancer by creating energy depletion and preventing metabolic switch","volume":"19","author":"Aisu","year":"2024","journal-title":"PLOS ONE"},{"key":"B13","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fonc.2020.00281","article-title":"Metabolic plasticity in chemotherapy resistance","volume":"10","author":"Desbats","year":"2020","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/cells7030021","article-title":"Elucidating the metabolic plasticity of cancer: mitochondrial reprogramming and hybrid metabolic states","volume":"7","author":"Jia","year":"2018","journal-title":"Cells"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1007\/s12015-025-10956-y","article-title":"Metabolic plasticity and cancer stem cell metabolism: exploring the Glycolysis-OXPHOS switch as a mechanism for resistance and tumorigenesis","volume":"21","author":"Keoh","year":"2025","journal-title":"Stem Cell Rev. Rep."},{"key":"B16","doi-asserted-by":"publisher","first-page":"153595","DOI":"10.1016\/j.prp.2021.153595","article-title":"The role of glycometabolic plasticity in cancer","volume":"226","author":"Peng","year":"2021","journal-title":"Pathol - Res Pract"},{"key":"B17","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12967-021-02889-0","article-title":"Pan-cancer characterization of metabolism-related biomarkers identifies potential therapeutic targets","volume":"19","author":"Bi","year":"2021","journal-title":"J Transl Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1186\/s12967-025-06722-w","article-title":"Recent advances and applications of mitochondria in tumors and inflammation","volume":"23","author":"Liu","year":"2025","journal-title":"J Transl Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"149382","DOI":"10.1016\/j.bbrc.2023.149382","article-title":"Mitochondrial metabolism as a dynamic regulatory hub to malignant transformation and anti-cancer drug resistance","volume":"694","author":"Tomar","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"B20","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1016\/S0021-9258(18)68925-2","article-title":"The effect of nonenzymatic glucosylation on the binding of the main noncollagenous NC1 domain to type IV collagen","volume":"263","author":"Tsilibary","year":"1988","journal-title":"J Biol Chem"},{"key":"B21","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04898-5","article-title":"Mitochondrial RNA modifications shape metabolic plasticity in metastasis","volume":"607","author":"Delaunay","year":"2022","journal-title":"Nature"},{"key":"B22","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41568-024-00786-4","article-title":"Metabolic interplays between the tumour and the host shape the tumour macroenvironment","volume":"25","author":"Altea-Manzano","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1073\/pnas.1816391116","article-title":"Elucidating cancer metabolic plasticity by coupling gene regulation with metabolic pathways","volume":"116","author":"Jia","year":"2019","journal-title":"Proc Natl Acad Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1002\/ijc.29839","article-title":"Metabolism in cancer metastasis","volume":"138","author":"Weber","year":"2016","journal-title":"Int J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41568-020-00320-2","article-title":"The metabolism of cancer cells during metastasis","volume":"21","author":"Bergers","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.tem.2012.06.010","article-title":"Emerging roles of PKM2 in cell metabolism and cancer progression","volume":"23","author":"Luo","year":"2012","journal-title":"Trends Endocrinol Metab"},{"key":"B27","doi-asserted-by":"publisher","first-page":"590576","DOI":"10.3389\/fcell.2020.590576","article-title":"Molecular crosstalk between MYC and HIF in cancer","volume":"8","author":"Li","year":"2020","journal-title":"Front Cell Dev. Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"eaay1212","DOI":"10.1126\/scisignal.aay1212","article-title":"Cancer cells with defective oxidative phosphorylation require endoplasmic reticulum\u2013to\u2013mitochondria Ca2+ transfer for survival","volume":"13","author":"Cardenas","year":"2020","journal-title":"Sci Signal"},{"key":"B29","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ccr.2012.11.020","article-title":"PGC1\u03b1 expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress","volume":"23","author":"Vazquez","year":"2013","journal-title":"Cancer Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.ccr.2013.02.003","article-title":"Oncogenic BRAF regulates oxidative metabolism via PGC1\u03b1 and MITF","volume":"23","author":"Haq","year":"2013","journal-title":"Cancer Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41416-022-01783-w","article-title":"PGC-1\u03b1 induced mitochondrial biogenesis in stromal cells underpins mitochondrial transfer to melanoma","volume":"127","author":"Kumar","year":"2022","journal-title":"Br J Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/1452696","article-title":"PGC-1 \u03b1, inflammation, and oxidative stress: an integrative view in metabolism","volume":"2020","author":"Rius-P\u00e9rez","year":"2020","journal-title":"Oxid Med Cell. Longev."},{"key":"B33","doi-asserted-by":"publisher","first-page":"35859","DOI":"10.1038\/srep35859","article-title":"Altered mitochondrial DNA copy number contributes to human cancer risk: evidence from an updated meta-analysis","volume":"6","author":"Hu","year":"2016","journal-title":"Sci Rep"},{"key":"B34","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41577-022-00760-x","article-title":"Mitochondrial control of inflammation","volume":"23","author":"Marchi","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1021\/acscentsci.4c02156","article-title":"Synergistic antitumor immunotherapy via mitochondria regulation in macrophages and tumor cells by an iridium photosensitizer","volume":"11","author":"Li","year":"2025","journal-title":"ACS Cent Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4663","DOI":"10.1038\/sj.onc.1209604","article-title":"Mitochondrial DNA mutations in human cancer","volume":"25","author":"Chatterjee","year":"2006","journal-title":"Oncogene"},{"key":"B37","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1038\/s41588-025-02374-0","article-title":"Functionally dominant hotspot mutations of mitochondrial ribosomal RNA genes in cancer","volume":"57","author":"Boscenco","year":"2025","journal-title":"Nat Genet"},{"key":"B38","doi-asserted-by":"publisher","first-page":"6320","DOI":"10.1245\/s10434-024-15759-y","article-title":"Mitochondrial DNA copy number as a biomarker for guiding adjuvant chemotherapy in stages II and III colorectal cancer patients with mismatch repair deficiency: seeking benefits and avoiding harms","volume":"31","author":"Chen","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1073\/pnas.94.2.514","article-title":"Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress","volume":"94","author":"Yakes","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.trecan.2022.08.001","article-title":"Mitochondrial DNA is a major source of driver mutations in cancer","volume":"8","author":"Kim","year":"2022","journal-title":"Trends Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s13238-019-0618-z","article-title":"PKM2 coordinates glycolysis with mitochondrial fusion and oxidative phosphorylation","volume":"10","author":"Li","year":"2019","journal-title":"Protein Cell"},{"key":"B42","doi-asserted-by":"publisher","first-page":"107538","DOI":"10.1016\/j.phrs.2024.107538","article-title":"Epithelial mitochondrial fission-mediated PANoptosis is crucial for ulcerative colitis and its inhibition by saquinavir through Drp1","volume":"210","author":"Ye","year":"2024","journal-title":"Pharmacol Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/nrm2952","article-title":"Mitochondria and cell death: outer membrane permeabilization and beyond","volume":"11","author":"Tait","year":"2010","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"3256","DOI":"10.1158\/1078-0432.CCR-21-3811","article-title":"VERONICA: randomized phase II study of fulvestrant and venetoclax in ER-Positive metastatic breast cancer Post-CDK4\/6 inhibitors - efficacy, safety, and biomarker results","volume":"28","author":"Lindeman","year":"2022","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1453886","DOI":"10.3389\/fimmu.2024.1453886","article-title":"Mitochondrial regulation in the tumor microenvironment: targeting mitochondria for immunotherapy","volume":"15","author":"Ahn","year":"2024","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.immuni.2012.10.020","article-title":"Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling","volume":"38","author":"Sena","year":"2013","journal-title":"Immunity"},{"key":"B48","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.immuni.2016.07.009","article-title":"The tumor microenvironment represses T cell mitochondrial biogenesis to drive intratumoral T cell metabolic insufficiency and dysfunction","volume":"45","author":"Scharping","year":"2016","journal-title":"Immunity"},{"key":"B49","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s41590-020-00834-9","article-title":"Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion","volume":"22","author":"Scharping","year":"2021","journal-title":"Nat Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.cell.2016.05.035","article-title":"Mitochondrial dynamics controls T cell fate through metabolic programming","volume":"166","author":"Buck","year":"2016","journal-title":"Cell"},{"key":"B51","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41590-021-00940-2","article-title":"Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity","volume":"22","author":"Guo","year":"2021","journal-title":"Nat Immunol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"5582","DOI":"10.1039\/D5BM01193K","article-title":"Current advancements in the investigation of mitochondria-targeting organic sensitizers in cancer immunotherapy","volume":"13","author":"Jing","year":"2025","journal-title":"Biomater Sci"},{"key":"B53","doi-asserted-by":"publisher","first-page":"JCI36843","DOI":"10.1172\/JCI36843","article-title":"Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice","volume":"118","author":"Sonveaux","year":"2008","journal-title":"J Clin Invest"},{"key":"B54","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/s41420-024-02277-9","article-title":"Mitochondria-targeted antioxidant MitoQ radiosensitizes tumors by decreasing mitochondrial oxygen consumption","volume":"10","author":"Rondeau","year":"2024","journal-title":"Cell Death Discov"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.3390\/cancers14061488","article-title":"MitoQ prevents human breast cancer recurrence and lung metastasis in mice","volume":"14","author":"Capeloa","year":"2022","journal-title":"Cancers"},{"key":"B56","doi-asserted-by":"publisher","first-page":"163","DOI":"10.3390\/antiox10020163","article-title":"Mitochondria-targeted antioxidants MitoQ and MitoTEMPO do not influence BRAF-driven malignant melanoma and KRAS-driven lung cancer progression in mice","volume":"10","author":"Le Gal","year":"2021","journal-title":"Antioxidants"},{"key":"B57","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.1200\/JCO.23.00296","article-title":"Effect of metformin versus placebo on new primary cancers in Canadian cancer trials group MA.32: a secondary analysis of a phase III randomized double-blind trial in early breast cancer","volume":"41","author":"Goodwin","year":"2023","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1001\/jama.2022.6147","article-title":"Effect of metformin vs placebo on invasive disease\u2013free survival in patients with breast cancer: the MA.32 randomized clinical trial","volume":"327","author":"Goodwin","year":"2022","journal-title":"JAMA"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1158\/1538-7445.AM2018-1655","article-title":"Abstract 1655: discovery and development of IACS-010759, a novel inhibitor of complex I currently in phase I studies to exploit oxidative phosphorylation dependency in acute myeloid leukemia and solid tumors","volume":"78","author":"Francesco","year":"2018","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10549-023-06922-2","article-title":"Metformin, placebo, and endocrine therapy discontinuation among participants in a randomized double-blind trial of metformin vs placebo in hormone receptor-positive early-stage breast cancer (CCTG MA32)","volume":"200","author":"Hershman","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1200\/JCO.23.02659","article-title":"Devimistat (CPI-613) with modified fluorouarcil, oxaliplatin, irinotecan, and leucovorin (FFX) versus FFX for patients with metastatic adenocarcinoma of the pancreas: the phase III AVENGER 500 study","volume":"42","author":"Philip","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1158\/1535-7163.MCT-23-0833","article-title":"Trametinib potentiates Anti-PD-1 efficacy in tumors established from chemotherapy-primed pancreatic cancer cells","volume":"23","author":"Pham","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B63","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s41580-023-00629-4","article-title":"Mechanisms of BCL-2 family proteins in mitochondrial apoptosis","volume":"24","author":"Czabotar","year":"2023","journal-title":"Nat Rev Mol Cell Biol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1007\/s12094-022-03070-9","article-title":"Bcl-2 pathway inhibition in solid tumors: a review of clinical trials","volume":"25","author":"Ploumaki","year":"2023","journal-title":"Clin Transl Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"6784","DOI":"10.1182\/blood-2024-207716","article-title":"Venetian: a phase 2b\/3 study to evaluate the risk of tumor lysis syndrome (TLS) and optimize initiation of venetoclax (ven) in patients with previously untreated chronic lymphocytic leukemia (CLL)","volume":"144","author":"Wierda","year":"2024","journal-title":"Blood"},{"key":"B67","volume-title":"The Safety of Venetoclax Base Regimens in Haematological and Solid Cancer: A Meta-Analysis of Randomized Controlled Trial; INPLASY - International Platform of Registered Systematic Review and meta-analysis Protocols","author":"Weng","year":"2023"},{"key":"B68","doi-asserted-by":"publisher","first-page":"102830","DOI":"10.1016\/j.pdpdt.2022.102830","article-title":"Targeting mitochondria for cancer photodynamic therapy","volume":"38","author":"Yaqoob","year":"2022","journal-title":"Photodiagnosis Photodyn Ther"},{"key":"B69","doi-asserted-by":"publisher","first-page":"e2304113","DOI":"10.1002\/advs.202304113","article-title":"Enhanced C-To-T and A-To-G base editing in mitochondrial DNA with engineered DdCBE and TALED","volume":"11","author":"Wei","year":"2024","journal-title":"Adv Sci"},{"key":"B70","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.cell.2023.11.035","article-title":"Engineering TALE-linked deaminases to facilitate precision adenine base editing in mitochondrial DNA","volume":"187","author":"Cho","year":"2024","journal-title":"Cell"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e001926","DOI":"10.1136\/jitc-2020-001926","article-title":"Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future","volume":"9","author":"Alzeibak","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"15015","DOI":"10.18632\/oncotarget.24551","article-title":"Modularity of the metabolic gene network as a prognostic biomarker for hepatocellular carcinoma","volume":"9","author":"Ye","year":"2018","journal-title":"Oncotarget"},{"key":"B73","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.cell.2015.12.034","article-title":"Metabolic heterogeneity in human lung tumors","volume":"164","author":"Hensley","year":"2016","journal-title":"Cell"},{"key":"B74","doi-asserted-by":"publisher","first-page":"E4410","DOI":"10.1073\/pnas.1501605112","article-title":"Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors","volume":"112","author":"Daemen","year":"2015","journal-title":"Proc Natl Acad Sci"},{"key":"B75","volume-title":"Cancer Center A Phase 1 Study to Evaluate the Safety and Tolerability of IACS-010759 in Subjects with Advanced Solid Tumors and Lymphoma","author":"Anderson","year":"2020"},{"key":"B76","doi-asserted-by":"publisher","first-page":"463","DOI":"10.3390\/jpm11060463","article-title":"Review of venetoclax in CLL, AML and multiple myeloma","volume":"11","author":"Lasica","year":"2021","journal-title":"J Pers Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.tcb.2018.04.002","article-title":"Metabolic hallmarks of metastasis formation","volume":"28","author":"Elia","year":"2018","journal-title":"Trends Cell Biol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"eaaw5473","DOI":"10.1126\/science.aaw5473","article-title":"Metabolic reprogramming and cancer progression","volume":"368","author":"Faubert","year":"2020","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1794130","DOI":"10.3389\/fimmu.2026.1794130","article-title":"Multidimensional tumor heterogeneity and its role in therapeutic resistance","volume":"17","author":"Mubin","year":"2026","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1038\/s41592-024-02392-6","article-title":"Integration of mass cytometry and mass spectrometry imaging for spatially resolved single-cell metabolic profiling","volume":"21","author":"Nunes","year":"2024","journal-title":"Nat Methods"},{"key":"B81","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s42255-025-01293-y","article-title":"Cell-intrinsic metabolic phenotypes identified in patients with glioblastoma, using mass spectrometry imaging of 13C-Labelled glucose metabolism","volume":"7","author":"Tsyben","year":"2025","journal-title":"Nat Metab"},{"key":"B82","doi-asserted-by":"publisher","first-page":"103579","DOI":"10.1016\/j.autrev.2024.103579","article-title":"Metabolic heterogeneity in tumor microenvironment \u2013 a novel landmark for immunotherapy","volume":"23","author":"Chen","year":"2024","journal-title":"Autoimmun Rev"}],"container-title":["Experimental Biology and Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.ebm-journal.org\/articles\/10.3389\/ebm.2026.11244\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:10:12Z","timestamp":1790572212000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ebm-journal.org\/articles\/10.3389\/ebm.2026.11244\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":82,"alternative-id":["10.3389\/ebm.2026.11244"],"URL":"https:\/\/doi.org\/10.3389\/ebm.2026.11244","relation":{},"ISSN":["1535-3699"],"issn-type":[{"value":"1535-3699","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"11244"}}